BIXINK THERAPEUTICS
BIXINK Therapeutics creates a new treatment paradigm with creativity and innovation. The company intends to become a company that becomes the source of a healthier life through the construction and convergence of technology that encompasses the times.
BIXINK THERAPEUTICS
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Content Delivery Network Font Awesome Mobile Non Scaleable Content Nginx Amazon Organization Schema Person Schema
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-12-07 | Limbix | BIXINK Therapeutics investment in Series A - Limbix | 15 M USD |
| 2020-05-05 | Limbix | BIXINK Therapeutics investment in Series A - Limbix | 9 M USD |
More informations about "BIXINK Therapeutics"
BIXINK
May 24, 2020 BIXINK, Breast cancer adjuvant treatment 'Nerlynx' has entered into Big 5 General Hospital 0 0 21 Sep 2022 ... 0 0 20 Jul 2022 Views 4020 Bixink Therapeutics signs deals to …See details»
BIXINK
빅씽크, 美 청소년 우울증 디지털 치료제 국내 독점 계약 체결See details»
BIXINK
Global drug market has been growing around synthetic chemicals, and is now accelerating its development through a variety of advanced technologies. We, therefore, aim to become a …See details»
BIXINK Therapeutics - Crunchbase Investor Profile & Investments
BIXINK Therapeutics creates a new treatment paradigm with creativity and innovation. The company intends to become a company that becomes the source of a healthier life through the …See details»
BIXINK Therapeutics investment portfolio - PitchBook
Founded in 2016, BIXINK Therapeutics is a venture capital investment firm based in Seoul, South Korea. The firm seeks to invest in the biotechnology, healthcare, and information technology …See details»
Blue Note Therapeutics and Bixink Enter Licensing Agreement for …
May 10, 2022 Featured Image for Blue Note Therapeutics, Inc. SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics and Bixink Therapeutics, a bio …See details»
BIXINK Therapeutics - Investments, Portfolio & Company Exits
Dec 7, 2021 BIXINK Therapeutics has had . 1. exit, which was Limbix. Which industries has this organization had the most exits in? Show . Limbix Limbix is a prescription digital therapeutics …See details»
Bixink Therapeutics - VentureRadar
Bixink Therapeutics is a biotech subsidiary of KPS Corp that focuses on building a diverse digital therapeutics (DTx) portfolio. The company has signed several DTx deals, including an …See details»
BIXINK Therapeutics - CB Insights
Jul 17, 2023 Boryung and Bixink to co-market Nerlynx for HER2-positive breast cancer. Apr 4, 2024. 닫기 Boryung (formerly Boryung Pharmaceutical), a strong player in the domestic …See details»
BIXINK
Everyone deserves a healthier tomorrow and happier lives. We support daily lives of those in need with dedication.See details»
Neratinib enters new turf | Drug Discovery News
Apr 30, 2020 Nerlynx is our top priority as we aspire to be a leading South Korean company in the field of oncology therapeutics,” added Dr. Sung Chul Kim, chief executive officer of Bixink …See details»
Blue Note Therapeutics and Bixink Enter Licensing Agreement
May 10, 2022 Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to serving patients suffering from cancer. We aim to make treatment accessible to …See details»
Puma Biotechnology and Bixink Therapeutics Enter into ... - BioSpace
Apr 30, 2020 Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs …See details»
Bixink Therapeutics and Professional Dietetics enter into …
Aug 5, 2021 Bixink Therapeutics and Professional Dietetics enter into partnership for the MUCOSAMIN® range, onco-supportive care, whereby Bixink will hold the exclusive …See details»
Bixink to bring new breast cancer drug to Korea
Bixink will commercialize NERLYNX® (neratinib) in South Korea Image credit- shutterstock.com US based Puma Biotechnology, Inc., a biopharmaceutical company, and Bixink Therapeutics, …See details»
MEDIA - BIXINK
Jul 20, 2022 Bixink Therapeutics signs deals to expand DTx pipelines Halimriadi Richar 24 May 2022 Views 4357 0; 12; Nerlynx in HER2-positive Early Breast Cancer, helping to overcome …See details»
Blue Note Therapeutics and Bixink Enter Licensing Agreement for …
SAN FRANCISCO - May 9, 2022 - (Newswire.com) Blue Note Therapeutics and Bixink Therapeutics, a bio-subsidiary of KPS, today announced that the companies have entered into …See details»
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive ...
Apr 30, 2020 Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs …See details»
BIXINK
"The first oral extended adjuvant therapy HER2 positive breast cancer" Neratinib, an oral HER2 targeted therapy, was approved by the U.S. Food and Drug Administration in 2017 and by the …See details»